United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck

Teva Pharmaceutical

You can go big this month with these three pharmaceutical stocks.

3 Smartest Big Pharma Stocks to Buy in September

AstraZeneca

Johnson & Johnson

Moderna

Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.

Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?

American Airlines

Alaska Air Group

BioNTech SE

Delta Air Lines

JetBlue Airways

Southwest Airlines

United Continental Hlds

Stocks like Delta (DAL), American Airlines (AAL) and Southwest (LUV) gain on Thursday despite the Delta variant-induced dull warnings.

Why U.S. Airline Stocks Gained Yesterday Despite Dim Views

The Pfizer-BioNTech vaccine got emergency authorization for kids age 12-15 in May.

Pfizer to seek approval for COVID-19 vaccine in kids age 5 and older in coming weeks, report says

BHP Billiton

Coca-Cola

Some investors prefer to buy stocks for the long-term. They should consider these stocks under $100 with sustainable business models.

3 Stocks Under $100 to Buy and Hold Forever

Myovant Sciences

Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.

Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA

The vaccine makers are almost ready to seek approval for the jab's use among children as young as five years old.

Pfizer-BioNTech To Seek Approval For First Covid Vaccine For Young Children ‘In Next Few Weeks'

Pfizer isn't resting on the laurels of its COVID vaccine success.

Could This Be Pfizer's Next Blockbuster Vaccine?

It's been a changing story about the details of the U.S. plan for booster shots.

Will There Be 6-Month or 8-Month COVID Boosters?

Pfizer could make billions in vaccine sales beyond COVID-19.

Here's the Next Blockbuster Vaccine Opportunity for Pfizer

AT&T

T-Mobile US

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Finding stocks that pay a decent dividend is a little more difficult in the current market than it has been in the past. The strong bull market combined with difficult economic conditions means that stock prices have skyrocketed, but dividend payments have not followed suit.

5 High-Dividend Stocks That Gurus Are Buying

Erasca Inc

Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.

Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study

European Medical Agency (EMA) has approved additional manufacturing sites to produce Comirnaty, the COVID-19 vaccine developed by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX). One site, located in Frankfurt, is operated by Sanofi-Aventis Deutschland GmbH, part of Sanofi SA (NASDAQ: SNY).

EMA Gives Nod To Additional Sites For Pfizer - BioNTech COVID-19 Vaccine

GlaxoSmithKline

Sanofi

GlaxoSmithKline PLC ( GSK , Financial) is forecasted to carve out more than 25% of a vaccine market that is expected to reach $10.5 billion by 2030. FiercePharma repotrted three other members of big pharma are also in line to be rewarded for developing a shot for respiratory syncytial virus, with Pfizer Inc. ( PFE , Financial) raking in $2.1 billion, Johnson & Johnson ( JNJ , Financial) adding $1.7 billion to its top line and Sanofi SA ( SNY , Financial) pocketing $1.2 billion.

Glaxo, Pfizer, J&J and Sanofi Expected to Grab Biggest Shares of RSV Vaccine Business

Pfizer and BioNTech shared huge commercial success with their Comirnaty COVID-19 vaccine. Despite that, BioNTech stock has significantly outperformed Pfizer stock, befuddling Pfizer's investors as its stock struggled to keep pace with BioNTech stock.

Pfizer Vs. BioNTech Stock: Which Is The Better Buy?

The US's average weekly vaccination rate has declined 38% since the FDA approved Pfizer's COVID-19 vaccine.

The FDA approval of Pfizer's vaccine didn't cause the uptick in vaccinations that people had hoped, data shows

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and over, who are candidates for systemic therapy. Abrocitinib is licensed in Great Britain in recommended doses of 100mg and

UK's MHRA Grants Marketing Authorisation for Pfizer's CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis

One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 180,000 shares of Pfizer Inc.

Cathie Wood's ARK Invest Buys Over 180,000 Shares of Pfizer

Researchers have been comparing the two vaccines in various studies.

Moderna Beats Pfizer by This 1 Measure. Here's Why Pfizer Investors Shouldn't Worry.

Boeing

Roku

Amazon

Cathie Wood-led Ark Invest on Tuesday sharply reduced its exposure in Boeing Co (NYSE:BA) a day after European budget airline Ryanair Holdings Plc (NASDAQ:RYAAY) called off talks with the planemaker for a potential 737 MAX 10 jet order, worth billions of dollars, due to differences over pricing. The popular money managing firm shed about one-third of the shares that it held in the planemaker via the Ark Space Exploration & Innovation ETF (BATS:ARKX).

Amazon, Pfizer, Roku, Boeing And More: These Are Cathie Wood's Key Trades From Tuesday

Roche Holding AG

Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage.

4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam

Novel 3CL protease inhibitor under development. Pivot in vaccination strategy telegraphed in Fox interview.

Pfizer's 3CL Protease Inhibitor May Cut The Achilles' Heel Of COVID-19

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer executives at two upcoming healthcare conferences. Frank D'Amelio, Chief Financial Officer, Executive Vice President, Global Supply, will hold a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 at 10:15 a.m. Eastern Daylight Time. Angela Hwang, Group President, Pfizer Biopharmaceuticals Group,

Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences

The Pfizer-BioNTech shot will likely be the only COVID-19 vaccine booster available by Sept. 20, the Biden administration's target date to begin offering them, but Dr. Anthony Fauci said Sunday that Moderna's shot shouldn't be too far behind.

Pfizer booster likely to be OK'd by Sept. 20, but Moderna's may lag, Fauci says

On Sunday, President Joe Biden's Chief Medical Adviser Dr. Anthony Fauci said officials would soon get the regulatory clearance to administer Covid-19 vaccine booster shots made by Pfizer Inc (NYSE: PFE). However, the Moderna Inc (NASDAQ: MRNA) booster could take a little longer.

News for Pfizer Stock (PFE)